Background: The prevalence of programmed cell death ligand-1(PD-L1) expression in non-small cell lung cancer (NSCLC) within unselected populations remains a research topic, though PD-L1 expression is important in guiding treatment decisions.
Objectives: The study objective was to ascertain the prevalence of PD-L1 expression in patients of NSCLC and its association with clinicopathological characteristics and other gene mutations.
Methods: Samples from patients with NSCLCs were analyzed in the study to determine the expression of PD-L1 through immunohistochemistry (IHC) using rabbit anti-human PDL-1/CD274 monoclonal antibody.